Orion Pharma, Qilu Partner On Pembrolizumab Biosimilar In Europe

Orion Corp. and Qilu Pharma Europe have entered into an agreement to commercialize an intravenous (IV) pembrolizumab biosimilar in Europe. Pembrolizumab is an immune checkpoint inhibitor used to treat various cancers.